Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Geary

Showing results (61-70 of 152) with videos related to

Pageof 16
Sort By:
Nucleic Acid Therapeutics|December 1, 2022
Integrated Assessment of Phase 2 Data on GalNAc<sub>3</sub>-Conjugated 2'-<i>O</i>-Methoxyethyl-Modified Antisense OligonucleotidesBrenda F Baker, Shuting Xia, Wesley Partridge, et al.
European Journal of Mass Spectrometry (Chichester, England)|July 28, 2005
Development of an ion-pair reverse-phase liquid chromatographic/tandem mass spectrometry method for the determination of an 18-mer phosphorothioate oligonucleotide in mouse liver tissueAnthony T Murphy, Patricia Brown-Augsburger, Rosie Z Yu, et al.
Journal of Pharmaceutical Sciences|December 4, 2003
Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeysRosie Z Yu, Richard S Geary, David K Monteith, et al.
Alimentary Pharmacology & Therapeutics|May 4, 2006
Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitisP B Miner, R S Geary, J Matson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancerC C Cunningham, J T Holmlund, J H Schiller, et al.
Clinical Pharmacokinetics|August 4, 2006
Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazoneRichard S Geary, JoAnn D Bradley, Tanya Watanabe, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 14, 1997
Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expressionR S Geary, J M Leeds, J Fitchett, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trialRohit Loomba, Erin Morgan, Lynnetta Watts, et al.
Archives of Environmental Contamination and Toxicology|October 1, 1994
The comparative metabolism of diisopropyl methylphosphonate in mink and ratsD J Weiss, R S Geary, W Wustenberg, et al.
Global Health Action|June 7, 2016
The gender dimensions of social networks and help-seeking behaviors of young adults in Soweto, South AfricaKathryn Meagley, Brittany Schriver, Rebecca S Geary, et al.
Pageof 16

Showing results (61-70 of 152) with videos related to

Sort By:
Pageof 16
Nucleic Acid Therapeutics|December 1, 2022
Integrated Assessment of Phase 2 Data on GalNAc<sub>3</sub>-Conjugated 2'-<i>O</i>-Methoxyethyl-Modified Antisense OligonucleotidesBrenda F Baker, Shuting Xia, Wesley Partridge, et al.
European Journal of Mass Spectrometry (Chichester, England)|July 28, 2005
Development of an ion-pair reverse-phase liquid chromatographic/tandem mass spectrometry method for the determination of an 18-mer phosphorothioate oligonucleotide in mouse liver tissueAnthony T Murphy, Patricia Brown-Augsburger, Rosie Z Yu, et al.
Journal of Pharmaceutical Sciences|December 4, 2003
Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeysRosie Z Yu, Richard S Geary, David K Monteith, et al.
Alimentary Pharmacology & Therapeutics|May 4, 2006
Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitisP B Miner, R S Geary, J Matson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2000
A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continuous intravenous infusion in patients with advanced cancerC C Cunningham, J T Holmlund, J H Schiller, et al.
Clinical Pharmacokinetics|August 4, 2006
Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazoneRichard S Geary, JoAnn D Bradley, Tanya Watanabe, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 14, 1997
Pharmacokinetics and metabolism in mice of a phosphorothioate oligonucleotide antisense inhibitor of C-raf-1 kinase expressionR S Geary, J M Leeds, J Fitchett, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trialRohit Loomba, Erin Morgan, Lynnetta Watts, et al.
Archives of Environmental Contamination and Toxicology|October 1, 1994
The comparative metabolism of diisopropyl methylphosphonate in mink and ratsD J Weiss, R S Geary, W Wustenberg, et al.
Global Health Action|June 7, 2016
The gender dimensions of social networks and help-seeking behaviors of young adults in Soweto, South AfricaKathryn Meagley, Brittany Schriver, Rebecca S Geary, et al.
Pageof 16